Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2007

01-05-2007 | Research Articles

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

Authors: L. G. Estévez, P. Sánchez-Rovira, M. Dómine, A. León, I. Calvo, A. Jaén, V. Casado, G. Rubio, M. Díaz, C. Miró, F. Lobo, E. Carrasco, M. Casillas, B. San Antonio

Published in: Clinical and Translational Oncology | Issue 5/2007

Login to get access
Metadata
Title
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study
Authors
L. G. Estévez
P. Sánchez-Rovira
M. Dómine
A. León
I. Calvo
A. Jaén
V. Casado
G. Rubio
M. Díaz
C. Miró
F. Lobo
E. Carrasco
M. Casillas
B. San Antonio
Publication date
01-05-2007
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2007
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-007-0059-7

Other articles of this Issue 5/2007

Clinical and Translational Oncology 5/2007 Go to the issue

Educational Series

Molecular determinants of invasion in endometrial cancer

News and Views

High tension: oncologic pain

Case Reports

False-positive β-human chorionic gonadotropin values in the follow-up of gestational trophoblastic disease

Case Reports

Non-seminomatous germ-cell tumour associated with acute megakaryoblastic leukaemia

Research Articles

Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients

Educational Series

Cancer epidemiology: study designs and data analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits